BioNTech Adds Two ADCs in Second Deal in as Many Months

With the COVID-19 pandemic entering a new phase, BioNTech is refocusing on its first ambition—cancer therapeutics. Monday, the German company announced the addition of two new antibody-drug conjugates (ADCs) for solid tumors to its portfolio.